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Summary
Niemann-Pick type II disease is an autosomal recessive
disorder characterized by a defect in intracellular traf-
ficking of sterols. We have determined the intron/exon
boundaries of eight exons from the conserved 3′ portion
of NPC1, the gene associated with most cases of the
disease. SSCP analyses were designed for these exons
and were used to identify the majority of mutations in
13 apparently unrelated families. Thirteen mutations
were found, accounting for 19 of the 26 alleles. These
mutations included eight different missense mutations
(including one reported by Greer et al. [1998]), one 4-
bp and two 2-bp deletions that generate premature stop
codons, and two intronic mutations that are predicted
to alter splicing. Two of the missense mutations were
present in predicted transmembrane (TM) domains.
Clustering of these and other reportedNPC1mutations
in the carboxy-terminal third of the protein indicates
that screening of these exons, by means of the SSCP
analyses reported here, will detect most mutations. The
carboxy-terminal half of the Npc1 protein shares
amino acid similarity with the TM domains of the mor-
phogen receptor Patched, with the largest stretch of
unrelated sequence lying between two putative TM
spans. Alignment of this portion of the human Npc1
protein sequence with Npc1-related sequences from
mouse, yeast, nematode, and a plant, Arabidopsis, re-
vealed conserved cysteine residues that may coordinate
the structure of this domain. That 7 of a total of 13
NPC1 missense mutations are concentrated in this sin-
gle Npc1-specific domain suggests that integrity of this
region is particularly critical for normal functioning of
the protein.
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Introduction
Niemann-Pick type II disease is a fatal lipid-storage dis-
order with autosomal recessive inheritance (Spence and
Callahan 1989; Pentchev et al. 1995). The underlying
defect is a disruption in the intracellular trafficking of
sterols, which leads to an accumulation of unesterified
cholesterol within the lysosomal compartment of the cell
(Liscum and Klansek 1998; Morris and Carstea 1998;
Watari et al. 1999). This perturbation of sterol home-
ostasis particularly affects the functioning of cells in the
brain, liver, and spleen. Although the age at onset of
Niemann-Pick type II disease is variable, affected indi-
viduals normally present clinically, at preschool age,
with ataxic gait and hepatosplenomegaly, with eventual
progression to dementia, dysarthria, dystonia, and sei-
zures. Affected individuals typically die during their teen
years. Traditionally, Niemann-Pick type II disease has
been divided into two entities: type C (NPC [MIM
257220]) and type D (NPD [MIM 257250]). NPD, the
Nova Scotia variant, was distinguished by its less severe
phenotype and by the Acadian ancestry of affected in-
dividuals (Winsor and Welch 1978; Greer et al. 1999).
Complementation studies, in which somatic-cell hy-
brids of fibroblasts from different patients with Nie-
mann-Pick type II disease were assayed for correction of
their biochemical defect, provided evidence for at least
two genes, mutations in either of which result in clini-
cally and biochemically indistinguishable disease (Stein-
berg et al. 1994; Vanier et al. 1996). The NPC1 gene,
which is associated with ∼80% of cases, has recently
been isolated from the proximal region of chromosome
18q, by use of a strategy of linkage analysis and posi-
tional cloning (Carstea et al. 1993, 1997). NPD was
subsequently demonstrated to be an allelic variant of
NPC1 (Greer et al. 1997, 1998).
Although the function of the Npc1 protein is un-
known, the sequence of the NPC1 gene predicts a
1,278-amino-acid protein with 13–16 possible trans-
membrane (TM) domains; a signal sequence that would
direct its synthesis at the endoplasmic reticulum; a leu-
cine zipper motif, located in the amino-terminal region,
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Figure 1 NPC1 mutations. Maps of (a) the 3′ end of the NPC1 gene and (b) the cDNA are shown. The positions of exons A–H are
represented by squares, and introns are represented by lines. The positions of two intronic mutations are indicated. c, Diagram of the Npc1
protein aligned with the cDNA, showing the correspondence between the exons and their encoded amino acid sequence. Predicted domains
within the Npc1 protein are indicated by squares shaded as follows: squares with diagonal stripes represent signal sequence; light gray–shaded
squares, leucine zipper; dark gray–shaded squares, TM regions; and blackened squares, lysosomal targeting signal (Carstea et al. 1997). Regions
of the Npc1 protein sharing 125% amino acid identity with the human Ptch1 protein are underlined. The positions of all reported NPC1
mutations in the coding sequence are represented along the protein as follows: blackened circles, missense mutations; unblackened triangles,
deletions; and carats, insertions. Unless otherwise indicated, deletions and insertions result in frameshifts that introduce premature stop codons.
d, Alignment of the amino acid sequence for the human (Hu) Npc1 domain between TM spans 9 and 10 with the corresponding regions from
Npc1-related sequences from mouse (Mus Npc1), S. cerevisiae (Sc Ncr1), A. thaliana (GenBank accession number AL035539), and C. elegans
(GenBank accession numbers U53340 and L11247). Asterisks indicate an identical residue at that position in all six sequences; dots, conservative
amino acid substitutions; diamond, a position where a cysteine occurs in all sequences except that of A. thaliana, for which a histidine is
substituted; dashes, gaps that are introduced to maximize the alignment; blackened circles above the alignment (with the letter, above the
blackened circle, indicating the amino acid substitution), positions of missense mutations identified in this region in patients with Niemann-
Pick type II disease; and unblackened triangles, positions of frameshifts created by deletions.
that may mediate interactions with additional pro-
tein(s); and a carboxy-terminal dileucine (LLNF) ly-
sosomal targeting signal (Carstea et al. 1997) (fig. 1).
Orthologues sharing sequence conservation with the
human Npc1 protein throughout their length have been
identified in nematode, yeast, and mouse (Carstea et
al. 1997; Loftus et al. 1997), which suggests that the
function of this protein has also been conserved
through evolution. The Npc1 protein shares significant
similarity, throughout most of its TM spans, with the
TM domains of a plasma membrane–localized protein,
Patched1 (Ptch1) (Johnson et al. 1996; Carstea et al.
1997) (fig. 2). The PTCH1 gene has also been con-
served, through evolution, with homologues and a par-
alogue, the PTCH2 gene, which has been identified in
Drosophila, mice, and humans (Goodrich et al. 1996,
reviewed in Hammerschmidt et al. 1997). Ptch1 func-
tions both in embryonic development and in tumor
suppression, acting as part of the receptor for Sonic
hedgehog, a secreted protein originally identified, in
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Figure 2 Comparison of human Npc1 and Ptch1 proteins. A
model for the organization of Npc1 within the lysosomal membrane
is contrasted with the proposed topology of human Ptch1 in the plasma
membrane (Goodrich et al. 1996; Johnson et al. 1996). The model is
a revision of that presented by Beachy et al. (1997). In the bottom
portion of this figure, predicted TM domains for Npc1 (Carstea et al.
1997) and Ptch1 are numbered and are shown as cylinders. Stretches
of amino acid sequence sharing 125% identity between the two pro-
teins are gray shaded. A region with homology to sterol-sensing do-
mains in Ptch1 (TM spans 2–6), HMG-CoA reductase, and SCAP
(Carstea et al. 1997) is indicated. The cysteine-rich Npc1-specific do-
main is overlined and is shown in an expanded form at the top of the
figure. To allow the conserved cysteine residues to be in close proximity
to one another, the domain is depicted as three hypothetical loops.
Blackened circles represent cysteine residues, and gray-shaded circles
represent other positions conserved between human Npc1 and the five
Npc1-related sequences. Conserved amino acid–sequence motifs in this
domain are indicated by the single-letter code for the amino acid—by
h for hydrophobic residues or by x for any amino acid.
Drosophila, by its role in the determination of segment
polarity. A region with homology to five of the con-
secutive TM spans shared between Ptch1 and Npc1 is
also found in two other proteins, SCAP (sterol regu-
latory element–binding protein [SREBP] cleavage-ac-
tivating protein) and 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase (Carstea et al. 1997),
both of which are regulated by sterols. This common
domain has been implicated in the ability of these latter
two endoplasmic reticulum–localized proteins to sense
sterol levels. Higher cholesterol levels increase the sus-
ceptibility of HMG-CoA reductase, a key enzyme in
the sterol biosynthetic pathway, to proteolysis (Gold-
stein and Brown 1990), whereas lower cholesterol lev-
els trigger activation of SCAP, which leads to proteo-
lytic release of the transcription factors required for
activation of genes encoding proteins involved in sterol
synthesis and uptake (Brown and Goldstein 1997).
That this sterol-sensing domain is present in Npc1 sug-
gests that it may also be regulated by the level of sterols
in the cell.
Carstea et al. (1997) previously reported eight NPC1
mutations in nine unrelated patients. With the exception
of a 6-bp deletion and a frameshift mutation, all iden-
tified mutations were in the carboxy-terminal third of
the protein. That the NPD mutation is also located in
the 3′ end of the coding region (Greer et al. 1998) sug-
gests that a large proportion of patients with Niemann-
Pick type II disease have mutations affecting the latter
third of the gene. Here, we report the intron/exon
boundaries of the eight exons from this region, the de-
velopment of SSCP analyses for use in the detection of
mutations in this portion of NPC1, and 12 new NPC1
mutations.
Patients, Material, and Methods
Patients
All patients evaluated in this study were referred either
with a diagnosis of Niemann-Pick type II or for evalu-
ation of the possibility of this diagnosis. These patients
included one individual from Nova Scotia (3114), two
from New Brunswick (3081 and 3093), seven from cen-
tral or western Canada (3118–3122, 3124, and 3125),
and one from Maryland (3123). Diagnosis was con-
firmed biochemically, at the Izzak Walton Killam (IWK)
Grace Health Centre, by measurement of LDL-stimu-
lated cholesterol esterification and by filipin fluorescence
(Pentchev et al. 1995). Biochemical defects were scored
either as “severe” (characterized by intense perinuclear
filipin staining and absence of cholesterol esterification,
relative to that seen in NPC control cell line GM3123)
or as “moderate” (characterized by intermediate filipin
staining and/or partial LDL stimulation, for 6–18 h, of
cholesterol esterification, as noted elsewhere [Sidhu et
al. 1993] for NPD fibroblasts). DNA samples were also
obtained from the parents of an affected NPC patient
whose paternal grandparents (3034 and 3035) lived in
Nova Scotia and from affected siblings (3056 and 3066)
with reported Nova Scotian ancestry. The 13 families
were apparently unrelated. DNA was extracted from
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Table 1
Primer Sequences for SSCP Analyses of Exons A–H
Exon
cDNA Position
of Exona Primer Sequences
Amplicon
Size
(bp)
GenBank
Accession
Number
A 3755–4101 Forward, TCC AAA GTG GGA TTA CAGG
Reverse, CCT TAG ACA CAG TTC AGT CAGG
209 AF125033
B 3592–3754 Forward, GGT TGG TAA AAG TGG GTTC
Reverse, GAA AAG AAT GCC TCA GGATA
284 AF125034
C 3478–3591 Forward, GGG TGC CCT GGG TAAT
Reverse, CTT TGT GGT GCG ACT CTG
250 AF125035
D 3246–3477 Forward, GCG AGC TTT AAT GAG GCC TCC
Reverse, CCA AAC TGA GAC TGT ATG AGG A
294 AF125036
E 3042–3245 Forward, TGC TTA GCC TCA AGT GCTC
Reverse, CCC TTT GCT GGT AAA CCC
324 AF125037
F 2912–3041 Forward, CTT CTA ACA GTC CTC CCT GCA
Reverse, CTG TCT TAG CCC AGT CCT CTC
248 AF125038
G 2796–2911 Forward, GTG GAG CAG GTC TGT AAC C
Reverse, CAG CAA AAC GGG AAA GAT
190 AF125039
H 2605–2795 Forward, TGT TCA CAC TCT CTC CTA TCT TCTA
Reverse, CCT CCG CTG CTT CTG A
268 AF125040
a On the cDNA, where the A of the initiation codon is taken as number 1.
peripheral blood lymphocytes or from fibroblast cell cul-
tures that were collected with ethical approval.
Characterization of Intron/Exon Boundaries
The entire NPC1 cDNA was amplified, in three sec-
tions, by means of PCR; it was then cloned in a TA
cloning vector (pCR 2.1 Invitrogen) and was sequenced
to confirm that it matched the sequence reported else-
where (Carstea et al. 1997). Primers generated from the
cDNA sequence (GenBank AF002020) were used to ob-
tain genomic amplicons, which were also cloned and
sequenced. Intron/exon boundaries flanking exons A–H
(fig. 1) from the 3′ end of the gene were identified in a
comparison of the sequence of genomic DNA clones
with that of cDNA. The size of the intervening sequences
was estimated on the basis of the size of PCR amplicons
generated from genomic DNA that span adjacent exons.
SSCP Analysis
The sequence of the introns flanking exons A–H was
used to generate primers for use in SSCP analysis of each
exon. Primers are described in table 1. All eight exons
were amplified under the following conditions: initial
denaturation at 95C for 5 min and 30 cycles of dena-
turation at 95C for 30 s, annealing at 55C for 30 s,
and extension at 72C for 1 min. Reaction mixtures (20
ml) contained 10 mM Tris-HCl (pH 9.0), 1.5 mM MgCl2,
50 mM KCl, 500 mg BSA/ml, 250 mM each dNTP, 5 mCi
a[32P]-dCTP, 0.5 U Taq polymerase (Gibco BRL), 1 mM
each primer, and 500–1,000 ng genomic DNA. (Exons
B and C were amplified with an alternate buffer: 25 mM
Tris [pH 8.3], 2 mM MgCl2, 1 mM DTT, and 50 mM
KCl.) Amplicons from all exons were analyzed by means
of SSCP, according to methods described elsewhere
(Hayashi 1991). In brief, mutations were detected by
separation of denatured amplicons on 8% nondenatur-
ing polyacrylamide gels in both Tris-borate EDTA buffer
and varied glycerol concentrations—0%, 5%, or 10%.
These gels were run for 17 h at 3W, 5W, or 7W, re-
spectively.
Sequence Analysis
The sequence of amplified products with aberrant
SSCP patterns was determined by use of a Thermo
Sequence radiolabeled terminator cycle sequencing kit
(Amersham Life Science) and by separation of the la-
beled reactions on denaturing polyacrylamide gels and
by exposure of the gels to x-ray film for 24 h. Se-
quences related to human Npc1 (GenBank accession
number AAB63982) were identified by means of
BLASTP searches (Altschul et al. 1997) and were
aligned with the use of CLUSTAL W (1.7) (Thompson
et al. 1994). Related sequences that were used in the
alignments are as follows: mouse Npc1 (GenBank ac-
cession number AAB63372 ), yeast (Saccharomyces
cerevisiae) Ncr1 (GenBank accession number
S52525), human Ptch1 (GenBank accession number
AAC50550), and three putative proteins identified in
genome sequences from Arabidopsis thaliana
(GenBank accession number AL035539) and Caenor-
habditis elegans (GenBank accession numbers
U53340 and L11247). The amino acid sequences that
we derived for the putative proteins from AL035539
and L11247 differ from those determined by use of
the Genefinder program (authors’ unpublished data).
Throughout its length, the A. thaliana sequence is as
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Table 2
Mutations in Families with NPC
Family Patient (Sex) Exon Mutation Predicted Protein Alteration Biochemical Defecta
1 3114 E
F
T3182C
G2974T
Ile1061Thr
Gly992Trp
Moderate
2 3081 B
G
T3637G
G2842A
Leu1213Val
Asp948Asn
Severe
3 3093 E T3182C Ile1061Thr Severe
4 3125 E
G
T3182C
G2801A
Ile1061Thr
Arg934Gln
Severe
5 3124 G C2861T Ser954Leu Severe
6 3121 ) None detected None Severe
7 3120 )
)
Intronic insertionb
Intronic deletionb
Splicing defect?
Splicing defect?
Severe
8 3123 G C2819T Ser940Leu Moderate
9 3118 F
F
C3019G
C3019G
Pro1007Ala
Pro1007Ala
Moderate
10 3119 F DAG (2972–2973) Frameshift Severe
11 3122 F DAG (2963–2964) Frameshift Severe
12 3034 (Female)
3035 (Male)
G
B
G2842A
DACTC (3741–3744)
Asp948Asn
Frameshift
ND
13 3056/3066 E
G
T3182C
G2801A
Ile1061Thr
Arg934Gln
ND
a ND = no data.
b For details, see text.
closely related to the human and mouse Npc1 proteins
as it is to the yeast Ncr1 protein, and it is more similar
to the vertebrate sequences than are either of the C.
elegans sequences (authors’ unpublished data).
Results
NPC1 Genomic Structure
Overlapping genomic DNA clones were generated
with the use of PCR primers previously used for se-
quencing NPC1 cDNA. By comparison of the genomic
DNA and cDNA sequences, eight exons (designated
“A”–“H”) were identified in the carboxy-terminal end
of NPC1, which is where the majority of mutations had
been identified in a previous study (Carstea et al. 1997).
The position of each exon in the cDNA is indicated in
table 1. Base-pair positions are numbered, starting at the
initiating ATG codon of the NPC1 open reading frame.
The genomic structure of this region and the approxi-
mate size of intervening sequences are shown in figure
1a.
Mutation Analysis
To allow the examination of the NPC1 coding re-
gion and splice sites for mutations associated with
each patient, primers were generated from intronic
sequence. Each of the eight carboxy-terminal exons
and their flanking intervening sequences were PCR
amplified, with the use of the primers shown in table
1 and with genomic DNA used as a template; they
were then assayed for SSCP. Amplicons with abnormal
migration were sequenced.
Thirteen patients (two brothers represented one “pa-
tient,” and both parents of a deceased patient repre-
sented another “patient”), comprising a total of 26 al-
leles, were analyzed. Nineteen mutant alleles were
identified and are described in table 2. Nine alleles had
unique mutations, two alleles were found for each of
three further mutations, and one mutation accounted
for four alleles. Only one patient was found to be a
homozygote.
One of the mutations identified in family 12, a 4-bp
deletion (DACTC3741–DACTC3744), and the 2-bp dele-
tions detected in families 10 and 11 (DAG2972–DAG2973
and DAG2963–DAG2964, respectively) generated frame-
shifts and premature stop codons. Eight missense mu-
tations were identified. One of these missense muta-
tions, found in patient 3114, was a G2974rT
transversion in exon F, described elsewhere as the NPD
mutation (Greer et al. 1997). The same patient’s second
allele showed a T3182rC transition that replaces a hy-
drophobic isoleucine at position 1061 by a hydrophilic
threonine residue in a predicted TM domain. This latter
allele was also observed in patients 3056, 3093, and
3125. A second predicted TM domain was altered by
a T3637rG transversion that changed Leuc1213Val in
patient 3081. The remaining five missense mutations
(Arg934Gln, Ser940Leu, Asp948Asn, Ser954Leu, and
Pro1007Ala) , a long with the NPD mutat ion
Gly992Trp, generate nonconservative amino acid
changes and are located in a single region flanked by
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the putative TM spans 9 and 10. The two remaining
mutations potentially alter splicing in both alleles of
patient 3120. One allele has a 1-bp deletion 10 bp
upstream from exon F, whereas the second allele has a
1-bp insertion 9 bp upstream from exon F. As indicated
in table 2, all mutations were identified in exons E, F,
or G, with the exception of two mutations in exon B
and the two intronic mutations that were 3′ to exon F.
Mutations were not identified in any of the exons an-
alyzed in patient 3121. Fifty unaffected individuals
were screened, by SSCP, for the mutations reported
here, none of which were found.
Distribution of Identified Mutations in NPC1
The positions of all NPC1 mutations identified in the
present study, plus the positions of those previously
reported (Carstea et al. 1997; Greer et al. 1998), are
shown, with respect to the Npc1 protein sequence, in
figure 1. To determine the likely significance of the ap-
parent clustering of the missense mutations, particu-
larly in the region between Npc1 TM regions 9 and
10, the amino acid sequences of the five Npc1 ortho-
logues and putative homologues that were identified
from BLASTP searches were aligned with the human
Npc1 sequence, to ascertain whether the altered resi-
dues represented conserved positions (fig. 1d). Only
two of the eight missense mutations (Pro1007Ala and
Leu1213Val) affected conserved amino acids.
Discussion
The recent identification of the NPC1 gene (Carstea
et al. 1997) has provided an opportunity to elucidate
the nature of the mutations responsible for Niemann-
Pick type II disease. We have identified the intron/exon
boundaries of eight exons from the conserved 3′ portion
of the coding sequence. On the basis of this finding, SSCP
analysis was designed and was used to identify 19 of 26
NPC1 mutant alleles from 13 families. This may be an
underestimation of the number of mutations in this re-
gion, since some mutations may not result in altered
electrophoretic mobility of the DNA, in SSCP analysis.
This may explain the inability to detect an NPC1 mu-
tation in one patient (3121) referred for diagnosis. Al-
ternatively, this individual may have mutations either in
a more proximal portion of the NPC1 gene or in another
gene, such as NPC2, that would create a similar
phenotype.
The two mutant alleles reported in patient 3114 were
identified by sequencing the entire coding region of the
respective cDNAs. Since both mutations result in non-
conservative amino acid substitutions and since no other
sequence change was noted, they almost certainly rep-
resent the causative defects. Indeed, one allele was pre-
viously confirmed to be the NPD mutation (Greer et al.
1998); the other allele alters the charge within a pre-
dicted TM span and therefore may affect interaction of
the protein with the membrane.
The remaining 11 mutations were identified by means
of SSCP analysis of eight exons from the 3′ region of the
gene. It is possible that some of these changes represent
silent polymorphisms and that causative mutations exist
elsewhere in the gene; however, at least three of the re-
ported mutations can reasonably be expected to disrupt
gene function. The 2- and 4-bp deletions identified in
families 10, 11, and 12 result in frameshifts and pre-
mature stop codons that would lead to the expression
of truncated Npc1 proteins lacking the carboxy-terminal
lysosomal targeting motif. Transfection of a Chinese
hamster ovary NPC-model cell line (CT60) with a hu-
man NPC1 gene in which this motif was deleted resulted
in expression of protein that accumulated at the endo-
plasmic reticulum and that failed to correct the choles-
terol-trafficking defect of these cells (Watari et al. 1999).
Transport of the protein to the lysosome therefore ap-
pears to be essential for expression of its biological ac-
tivity; at the very least, all three deletions would be ex-
pected to disrupt Npc1 function, as a result of
mislocalization. In addition, the frameshifts created by
the deletions might also have effects on protein structure
and function.
The amino acid change (Leu1213Val) identified in pa-
tient 3081 is conservative. This type of change would
usually represent a nondisruptive polymorphism; how-
ever, a leucine at this position in the putative TM domain
is invariant among the human, mouse, yeast, Arabidop-
sis, and C. elegans homologues of Npc1 and at the ho-
mologous position in all available vertebrate Ptch1 and
Ptch2 sequences. Thus, it may be critical for proper func-
tioning of the protein.
In patient 3120, a mutation in the intronic sequence
close to the 3′ end of exon F was identified in each allele.
Sequence analysis showed both the deletion of a thy-
midine nucleotide 10 bp upstream of exon F in one allele
and the insertion of a deoxyadenosine nucleotide 9 bp
upstream of exon F in the other allele. Both alterations
reduce the length of an already vulnerably short tract of
pyrimidines adjacent to the consensus sequence at the 3′
splice site and could potentially disrupt splicing of this
intron.
Six missense mutations that produce nonconservative
amino acid substitutions were identified in a single 155-
amino-acid domain flanked by predicted TM spans 9
and 10 (fig. 1). What is striking is that 7 of the 13
reported missense mutations (Carstea et al. 1997; Greer
et al. 1998; present study) are clustered within an 80-
amino-acid stretch. Although this part of the protein
sequence shows similarity between human, mouse, Ar-
abidopsis, C. elegans, and yeastNPC1 homologues, only
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one of the mutations, Pro1007Ala, alters a residue that
is conserved at that position in the six Npc1-related se-
quences compared here. This region contains eight cys-
teine residues that are conserved in all six sequences,
with the exception of a single site, in the Arabidopsis
NPC1 orthologue, where histidine is substituted for cys-
teine (fig. 2). The conservation of these residues indicates
that they may be important in the determination of the
folding of this inter-TM domain, either through for-
mation of intramolecular disulfide bonds or by coordi-
nation of a metal ion. The latter possibility is supported
by the substitution of a histidine for a cysteine in one
of the putative orthologues. The cysteine-rich motif C-
x(4–5)-C-x(39–43)-C-C-x(8–10)-C-x(5–13)-C-x2-C/H-
x(28–40)-C (where x can be any amino acid and where
numbers refer to the length of the intervening sequence),
which was conserved here, bears some resemblance to
a motif known as the “RING finger” (Freemont 1993)
and, also, to a cysteine-rich motif in the regulatory do-
main of protein kinase C (PKC) (Ono et al. 1989). The
eight conserved residues (7Cys/1His or 6Cys/2His) of
the RING-finger motif and the PKC regulatory domain
bind two zinc atoms and fold into a single domain that
is similar to that of the better-characterized zinc fingers;
however, the sequence and length of the loops between
the zinc ligands are less conserved than they are in the
zinc-finger family of protein motifs (Hubbard et al.
1991; Freemont 1993). Although RING-finger domains
are found in many proteins involved in gene regulation,
their postulated role in DNA binding has not been es-
tablished. These motifs may, instead, mediate protein-
protein or protein-lipid interactions. The integrity of the
RING-finger domain has been shown to be essential for
the function of two yeast proteins, Vps18/Pep3 and
Vps11/Pep5, both of which are required for biogenesis
of vacuoles (the yeast equivalent of the lysosome) and
for sorting and transport of vacuolar enzymes (Robinson
et al. 1991). Interestingly, mutation of human Npc1 also
leads to a lysosomal defect, although, in this case, traf-
ficking of cholesterol is affected. The cysteine-rich reg-
ulatory domain of PKC has been shown to be essential
in the binding of phorbol esters to the enzyme (Ono et
al. 1989), so it is possible that the cysteine-rich motif in
Npc1 may similarly coordinate a structure capable of
direct interaction with cholesterol.
Five of the NPC1 missense mutations flank a con-
served Trp-(Ile/Leu)-Asp-x-(Tyr/Phe) motif, located at
position 942–946, that lies between two pairs of cysteine
residues within the cysteine-rich domain. The amino acid
changes produced by these mutations do not alter con-
served residues. However, they may affect the folding of
this subdomain and the relative positioning of the con-
served motif with respect to the rest of the domain or
to other protein(s) that interact with Npc1, thereby dis-
rupting Npc1 function.
The cysteine-rich domain is contained within a region
of Npc1 that shares no sequence similarity to the human
Ptch1 protein (fig. 2). The analogous region in Ptch1
forms an extracellular domain that interacts with Sonic
hedgehog and that may be regulated by the adjacent
sterol-sensing domain (Johnson et al. 1996). Although
the Npc1 protein is targeted to the lysosome (Neufeld
et al. 1999; Watari et al. 1999) rather than to the plasma
membrane, the extended sequence similarity of the ma-
jority of the TM spans of the two proteins suggests that
they should be similarly oriented in the membrane, plac-
ing the Npc1 domain lying between TM spans 9 and 10
in the lysosomal compartment, rather than in the cytosol
(fig. 2). This topology would give the Npc1 sterol-sens-
ing domain TM spans 4–8 the same orientation, with
respect to their cytosolic contacts, as that which is seen
in the homologous sterol-sensing domains in both
HMG-CoA reductase and SCAP in which the membrane
topology has been determined (Olender and Simon
1992; Nohturfft et al. 1998). It is tempting to speculate
that the Npc1 sterol-sensing domain regulates the ability
of the adjacent cysteine-rich conserved domain to me-
diate, either directly or indirectly, the transport of cho-
lesterol out of the lysosome, in response to altered sterol
levels in the lysosomal membrane.
The 13 NPC1 mutations described here are different
from the 8 NPC1 mutations reported elsewhere (Carstea
et al. 1997). From this small sample, it appears that a
wide diversity of mutations are associated with Nie-
mann-Pick type II disease; however, since the majority
(19 of 21) of those mutations now reported are located
in the distal third of the gene, an initial mutational anal-
ysis of the eight exons described here may be the most
rapid approach toward establishing a diagnosis and car-
rier status within newly identified families. In addition,
these observations suggest a critical role for this portion
of the protein, particularly the cysteine-rich conserved
domain within this region, in the mediation of Npc1
function.
Note added in proof.—Morris et al. (1999) have re-
cently reported the genomic organization of the com-
plete NPC1 gene.
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